S&P 500   3,384.76 (-2.33%)
DOW   27,544.67 (-2.79%)
QQQ   279.37 (-1.89%)
AAPL   114.17 (-0.76%)
MSFT   209.94 (-2.91%)
FB   276.85 (-2.79%)
GOOGL   1,578.31 (-3.35%)
AMZN   3,197.27 (-0.22%)
TSLA   416.97 (-0.87%)
NVDA   524.73 (-3.47%)
BABA   306.16 (-1.21%)
CGC   18.75 (-4.97%)
GE   7.33 (-3.93%)
MU   51.89 (-1.82%)
AMD   82.08 (+0.15%)
T   27.32 (-1.80%)
F   8.01 (-1.84%)
ACB   4.43 (-5.34%)
GILD   59.85 (-1.55%)
NFLX   485.92 (-0.48%)
NIO   26.00 (-4.27%)
BA   160.23 (-4.26%)
DIS   123.61 (-3.69%)
S&P 500   3,384.76 (-2.33%)
DOW   27,544.67 (-2.79%)
QQQ   279.37 (-1.89%)
AAPL   114.17 (-0.76%)
MSFT   209.94 (-2.91%)
FB   276.85 (-2.79%)
GOOGL   1,578.31 (-3.35%)
AMZN   3,197.27 (-0.22%)
TSLA   416.97 (-0.87%)
NVDA   524.73 (-3.47%)
BABA   306.16 (-1.21%)
CGC   18.75 (-4.97%)
GE   7.33 (-3.93%)
MU   51.89 (-1.82%)
AMD   82.08 (+0.15%)
T   27.32 (-1.80%)
F   8.01 (-1.84%)
ACB   4.43 (-5.34%)
GILD   59.85 (-1.55%)
NFLX   485.92 (-0.48%)
NIO   26.00 (-4.27%)
BA   160.23 (-4.26%)
DIS   123.61 (-3.69%)
S&P 500   3,384.76 (-2.33%)
DOW   27,544.67 (-2.79%)
QQQ   279.37 (-1.89%)
AAPL   114.17 (-0.76%)
MSFT   209.94 (-2.91%)
FB   276.85 (-2.79%)
GOOGL   1,578.31 (-3.35%)
AMZN   3,197.27 (-0.22%)
TSLA   416.97 (-0.87%)
NVDA   524.73 (-3.47%)
BABA   306.16 (-1.21%)
CGC   18.75 (-4.97%)
GE   7.33 (-3.93%)
MU   51.89 (-1.82%)
AMD   82.08 (+0.15%)
T   27.32 (-1.80%)
F   8.01 (-1.84%)
ACB   4.43 (-5.34%)
GILD   59.85 (-1.55%)
NFLX   485.92 (-0.48%)
NIO   26.00 (-4.27%)
BA   160.23 (-4.26%)
DIS   123.61 (-3.69%)
S&P 500   3,384.76 (-2.33%)
DOW   27,544.67 (-2.79%)
QQQ   279.37 (-1.89%)
AAPL   114.17 (-0.76%)
MSFT   209.94 (-2.91%)
FB   276.85 (-2.79%)
GOOGL   1,578.31 (-3.35%)
AMZN   3,197.27 (-0.22%)
TSLA   416.97 (-0.87%)
NVDA   524.73 (-3.47%)
BABA   306.16 (-1.21%)
CGC   18.75 (-4.97%)
GE   7.33 (-3.93%)
MU   51.89 (-1.82%)
AMD   82.08 (+0.15%)
T   27.32 (-1.80%)
F   8.01 (-1.84%)
ACB   4.43 (-5.34%)
GILD   59.85 (-1.55%)
NFLX   485.92 (-0.48%)
NIO   26.00 (-4.27%)
BA   160.23 (-4.26%)
DIS   123.61 (-3.69%)
Log in
NASDAQ:INMD

InMode Stock Forecast, Price & News

$40.20
-1.29 (-3.11 %)
(As of 10/26/2020 03:03 PM ET)
Add
Compare
Today's Range
$39.27
Now: $40.20▼
$41.71
50-Day Range
$32.07
MA: $36.85▼
$42.01
52-Week Range
$13.14
Now: $40.20▼
$58.76
Volume23,165 shs
Average Volume1.04 million shs
Market Capitalization$1.29 billion
P/E Ratio32.42
Dividend YieldN/A
Beta2.12
InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio frequency technologies. The company offers minimally-invasive aesthetic medical products for procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. InMode Ltd. offers its products directly in the United States, Canada, the United Kingdom, Spain, and India, as well as indirectly through third-party distributors internationally. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 2.5Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.56 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INMD
Previous Symbol
CUSIPN/A
CIK885988
Webwww.inmodemd.com
Phone972-4909-6313
Employees198

Debt

Debt-to-Equity RatioN/A
Current Ratio8.40
Quick Ratio7.81

Price-To-Earnings

Trailing P/E Ratio32.42
Forward P/E Ratio38.65
P/E GrowthN/A

Sales & Book Value

Annual Sales$156.36 million
Price / Sales8.22
Cash Flow$1.98 per share
Price / Cash Flow20.34
Book Value$5.62 per share
Price / Book7.15

Profitability

EPS (Most Recent Fiscal Year)$1.60
Net Income$61.15 million
Net Margins31.76%
Return on Equity27.15%
Return on Assets22.95%

Miscellaneous

Outstanding Shares31,973,000
Market Cap$1.29 billion
Next Earnings Date11/12/2020 (Confirmed)
OptionableNot Optionable
$40.20
-1.29 (-3.11 %)
(As of 10/26/2020 03:03 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive INMD News and Ratings via Email

Sign-up to receive the latest news and ratings for INMD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











InMode (NASDAQ:INMD) Frequently Asked Questions

How has InMode's stock been impacted by COVID-19 (Coronavirus)?

InMode's stock was trading at $24.40 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, INMD stock has increased by 64.3% and is now trading at $40.09.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of InMode?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InMode in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for InMode.

When is InMode's next earnings date?

InMode is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for InMode.

How can I listen to InMode's earnings call?

InMode will be holding an earnings conference call on Thursday, November 12th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were InMode's earnings last quarter?

InMode Ltd. (NASDAQ:INMD) announced its quarterly earnings results on Wednesday, August, 5th. The healthcare company reported $0.21 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.22) by $0.43. The healthcare company earned $30.80 million during the quarter, compared to analysts' expectations of $30.41 million. InMode had a net margin of 31.76% and a return on equity of 27.15%. The business's revenue was down 20.6% on a year-over-year basis.
View InMode's earnings history.

What guidance has InMode issued on next quarter's earnings?

InMode issued an update on its third quarter 2020 Pre-Market earnings guidance on Tuesday, October, 13th. The company provided EPS guidance of 0.60-0.62 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.31. The company issued revenue guidance of $59.2-59.5 million, compared to the consensus revenue estimate of $38.24 million.

What price target have analysts set for INMD?

4 Wall Street analysts have issued 12-month price targets for InMode's stock. Their forecasts range from $38.00 to $55.00. On average, they expect InMode's share price to reach $47.75 in the next year. This suggests a possible upside of 19.1% from the stock's current price.
View analysts' price targets for InMode.

Are investors shorting InMode?

InMode saw a decline in short interest in the month of September. As of September 15th, there was short interest totaling 1,870,000 shares, a decline of 15.8% from the August 31st total of 2,220,000 shares. Based on an average daily trading volume, of 697,100 shares, the short-interest ratio is presently 2.7 days. Currently, 11.5% of the shares of the company are short sold.
View InMode's Short Interest.

Who are some of InMode's key competitors?

Some companies that are related to InMode include Getinge (GNGBY), LivaNova (LIVN), CONMED (CNMD), CONMED (CNMD), Outset Medical (OM), BioLife Solutions (BLFS), Natus Medical (NTUS), AxoGen (AXGN), Zynex (ZYXI), Zynex (ZYXI), ViewRay (VRAY), Semler Scientific (SMLR), TransMedics Group (TMDX), Cutera (CUTR) and Stereotaxis (STXS).
View all competitors.

What other stocks do shareholders of InMode own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InMode investors own include NVIDIA (NVDA), Alibaba Group (BABA), salesforce.com (CRM), Micron Technology (MU), AbbVie (ABBV), Advanced Micro Devices (AMD), Square (SQ), Tesla (TSLA), Docusign (DOCU) and Paypal (PYPL).

Who are InMode's key executives?

InMode's management team includes the following people:
  • Mr. Moshe Mizrahy, Chairman & CEO (Age 66)
  • Mr. Yair Malca, Chief Financial Officer (Age 41)
  • Dr. Michael Kreindel, CTO & Director (Age 51)
  • Mr. Shakil Lakhani, Pres of North America (Age 35)
  • Dr. Spero Theodorou, Chief Medical Officer (Age 47)

When did InMode IPO?

(INMD) raised $75 million in an initial public offering on Thursday, August 8th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. ​Barclays, UBS Investment Bank and Canaccord Genuity served as the underwriters for the IPO and Baird was co-manager.

What is InMode's stock symbol?

InMode trades on the NASDAQ under the ticker symbol "INMD."

Who are InMode's major shareholders?

InMode's stock is owned by a number of institutional and retail investors. Top institutional investors include Hodges Capital Management Inc. (0.39%), Taylor Frigon Capital Management LLC (0.34%), Standard Life Aberdeen plc (0.08%), Acuitas Investments LLC (0.08%), Harel Insurance Investments & Financial Services Ltd. (0.02%) and Venture Visionary Partners LLC (0.02%).

Which institutional investors are selling InMode stock?

INMD stock was sold by a variety of institutional investors in the last quarter, including Standard Life Aberdeen plc, and Hodges Capital Management Inc..

Which institutional investors are buying InMode stock?

INMD stock was purchased by a variety of institutional investors in the last quarter, including Acuitas Investments LLC, Taylor Frigon Capital Management LLC, Venture Visionary Partners LLC, Aurora Private Wealth Inc., and Harel Insurance Investments & Financial Services Ltd..

How do I buy shares of InMode?

Shares of INMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is InMode's stock price today?

One share of INMD stock can currently be purchased for approximately $40.09.

How big of a company is InMode?

InMode has a market capitalization of $1.28 billion and generates $156.36 million in revenue each year. The healthcare company earns $61.15 million in net income (profit) each year or $1.60 on an earnings per share basis. InMode employs 198 workers across the globe.

What is InMode's official website?

The official website for InMode is www.inmodemd.com.

How can I contact InMode?

InMode's mailing address is TAVOR BUILDING SHAAR YOKNEAM POB 533, YOKNEAM L3, 2069200. The healthcare company can be reached via phone at 972-4909-6313 or via email at [email protected]

This page was last updated on 10/26/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.